Skip to main content
. 2013 Mar 12;21(5):1014–1023. doi: 10.1038/mt.2013.39

Figure 7.

Figure 7

Effect of VEGF blockade on the tumor microenvironment. Tumor-bearing animals were treated with either PBS (control) or oHSV by intratumoral injection and intraperitoneal IgG (control) or anti-VEGF antibodies r84 or bevacizumab. All treatments were given on day 0. Tumors were harvested on day +3 and analyzed for (a) tumor-derived hVEGF (n = 4–5), (b) host-derived mVEGF (n = 4–7), (c) CD11b+ cells by flow cytometry (n = 4) including neutrophils (CD11b+Gr1+F4/80−), myeloid-derived suppressor cells (CD11b+Gr1−F4/80−), and macrophages (CD11b+Gr1−F4/80+), and (d) MHC class II-positive macrophages. Error bars represent SEM. Bev, bevacizumab; hVEGF, human vascular endothelial growth factor; mVEGF, mouse vascular endothelial growth factor; IP, intraperitoneal; ITu, intratumoral; MDSC, myeloid-derived suppressor cell; MHC, major histocompatibility complex; oHSV, oncolytic herpes simplex virus; PBS, phosphate-buffered saline.